TerminatedPhase 2NCT00759876

Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
PTC Therapeutics
Principal Investigator
Leone Atkinson
PTC Therapeutics, Inc.
Intervention
Ataluren(drug)
Enrollment
36 enrolled
Eligibility
MALE
Timeline
20082010

Study locations (3)

Collaborators

Genzyme, a Sanofi Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00759876 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy

← Back to all trials